133 results about "Immune therapy" patented technology

The present application relates to the field of biomedicine, and in particular to a tumor antigen peptide and a use thereof. Provided is a tumor antigen peptide, comprising a peptide segment having an amino acid sequence as shown in SEQ ID NO: 1. The provided tumor antigen peptide can be presented by the HLA subtype (HLA-A*11:01) having a high proportion of Chinese population. Additionally, by means of in vitro stimulation, the tumor antigen peptide is verified to effectively stimulate specific T cells, and a specific TCR element is successfully obtained. The present application lays a direct foundation for further developing TCR-T therapy targeting human TP53 R248Q and immunotherapy such as therapeutic vaccines.

A method of determining the likelihood that a subject with cancer will respond to an immunotherapy comprising a checkpoint inhibitor. The method comprises detecting the level of histamine in a biological sample obtained from the subject. Subjects determined to have a low likelihood of responding to the immunotherapy can be administered an alternative therapy or administered an antihistamine in conjunction with the immunotherapy. Methods of treating cancer patients are also provided, as are kits and systems for histamine detection, recordation, and responder status determination.

Methods are disclosed related to identifying small molecule metabolites that serve as biomarkers of immune related adverse events (irAEs). In embodiments, treatments are disclosed that reduce the likelihood or prevent irAEs.

The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.

The present invention relates to a combination of urolithin and immunotherapy treatments, in particular a combination of urolithin and a therapeutic agent, in particular a combination of urolithin and immunotherapy treatments, such as a PD-1 antagonist, and an immune checkpoint blocking therapy. The invention also relates to pharmaceutical compositions comprising said combination, processes for the preparation of said pharmaceutical compositions and methods of using said compositions in the treatment of disease. In one embodiment, the immune checkpoint blocking therapy is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, or a fusion protein.

The present invention discloses a method for predicting the immune score of advanced lung cancer. The method comprises: obtaining slice image data of biological tissue of a patient to be predicted for lung cancer; improving the quality of the slice image data based on a neural network algorithm to obtain optimized image data; inputting the optimized image data into a feature extraction model to obtain a corresponding image feature vector; inputting the image feature vector into a trained immune therapy score prediction neural network to obtain the corresponding immune therapy effect of the patient to be predicted for lung cancer; the immune therapy score prediction neural network is trained using a training data set including multiple training tissue slice images and corresponding immune therapy score annotations. It can be seen that the present invention can achieve accurate immune therapy prediction directly based on images, reduce prediction costs, and improve prediction efficiency and accuracy.

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD122 / CD132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and / or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122 / CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.

To provide systems and methods for histotripsy and immune therapies.SOLUTION: In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.SELECTED DRAWING: Figure 1

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

The invention provides a traditional Chinese medicine composition for treating colorectal tumor by regulating immune function. The invention further provides a traditional Chinese medicine extract and a preparation method thereof. The invention further provides a traditional Chinese medicine preparation. The invention further provides application of the traditional Chinese medicine composition, the traditional Chinese medicine extract or the traditional Chinese medicine preparation in preparation of medicines for treating colorectal tumor. According to the traditional Chinese medicine composition for treating the colorectal tumor by adjusting the immune function and the preparation method thereof, the prepared traditional Chinese medicine composition has the effects of supporting body resistance, invigorating spleen and tonifying kidney, clearing away heat and toxic materials, activating blood and removing stasis, tonifying qi and reinforcing vital essence, and removing stasis and food retention, and can be used for improving the immunosuppression microenvironment of the colorectal tumor in cooperation with chemotherapy drugs; the anti-tumor immune function of a colorectal tumor patient is improved, the tumor development is inhibited, and a new thought is provided for the immunotherapy of the colorectal tumor.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical / therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector / substrate / support / scaffold for direct application.

The invention provides a nano delivery system based on copper death induction and application of the nano delivery system in preparation of tumor immunotherapy drugs, according to the novel copper death induction nano drug Cu / ZIF-90 (at) DSF, 30 mol% of Cu (acac) 2 and disulfiram are loaded through a high-porosity structure of ZIF-90, and pH / ROS dual-responsiveness copper ion release is achieved. Animal experiments show that the Cu < 2 + > accumulation concentration of the nano-drug at a tumor site reaches 23.7 mu M, and efficient copper death is induced (the apoptosis rate is 41.3% vs and the control group is 9.2%). More importantly, by releasing HMGB1 and ATP, the CD8 < + > T cell infiltration in a tumor microenvironment is increased by 5.8 times, and the CD8 < + > T cell infiltration and the alphaPD-1 antibody generate a synergistic effect, so that the complete remission rate is increased from 18% to 67%. According to the technical breakthrough, a brand new solution is provided for solving the cold tumor immunotherapy drug resistance.

Disclosed herein are methods of preventing or reducing the development of colorectal cancer in a subject identified as at risk of colorectal tumorigenesis. The methods include administering to the subject a composition comprising a zwitterionic capsular polysaccharide derived from a Bacteroides uniformis bacteria in an amount effective to prevent or reduce the development of colorectal cancer. Methods of treating colorectal cancer, reducing tumor size or tumor growth, inducing Natural Killer cell activity, and inducing Lag- 3 on Natural Killer cells are also provided.

Provided herein are methods for treating cancer in a patient in need thereof by determining that the patient is homologous recombination proficient (HRP); and administering an immunotherapy (e.g., cellular or gene therapy) to the patient (e.g., a tumor-infiltrating lymphocyte (TIL) therapy). The disclosure describes mechanism of clonal vs. subclonal neoantigen targeting, evidence of preclinical and clinical benefit related to clonal neoantigens with immune therapy, and Vigil® therapy designed to expand clonal neoantigen effector cell populations.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

Substituted benzofuran, benzothiophene, and indole carboxamide compounds, conjugates, and pharmaceutical compositions for use as immunotherapeutics in the treatment of cancer, such as solid tumors, are disclosed herein. The disclosed compounds are useful, among other things, in the treatment of a solid tumor originating in the breast, brain, kidney, ovary, cervix, pancreas, thyroid, colon, bladder, prostate, liver, stomach, or lung.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

Methods and systems for managing the dispensing of medications containing food allergens are described herein. Exemplary methods allow for registration of distributors, pharmacies, healthcare facilities, healthcare providers, and / or patients in a medication dispensing management database for the medication, where dispensing or provision of the medication is contingent upon securing one or more of the entities registered in the medication dispensing management database. Other methods for utilizing the medication dispensing management database are also described.

Disclosed herein is a platform capable of generating varying concentrations of antigens in cells. Also disclosed herein are methods for screening chimeric antigen receptors (CARs), including multitarget CARs (e.g. bi-specific, tri-specific), and CAR T cells capable of distinguishing between two cells with varying levels of the same antigen, using a highthroughput in vitro and / or in vivo approach with single domain antibodies. These methods offer a rapid way to obtain functional CAR T-cells and other modified immune cells to be used in, for example, the treatment of cancer. In some embodiments, the method / use is part of an immunotherapy treatment.

The present disclosure relates generally to compositions and methods for treating cancer. More specifically, the present disclosure relates to compositions and their use in one of altering the transformation of epithelial cells to mesenchymal cells or the transformation of mesenchymal cells to epithelial cells of tumor cells. The method comprises administering to the subject a composition comprising a PI3K inhibitor, such as paxalisib (GDC-0084), and an immunotherapy that is not targeted to cancer stem cells (CSC), wherein the immunotherapy is an immune checkpoint antagonist or a PARP inhibitor.

The invention relates to the technical field of biomedical engineering, and discloses a detection method for esophageal squamous carcinoma CTC enrichment and immunotherapy curative effect dynamic evaluation, and the method utilizes a micro-fluidic chip to carry out electrical impedance detection and physical preliminary screening on cells in a whole blood sample. And performing anti-reclosing time sequence verification on the screened interstitial circulating tumor cells, triggering transient flow resistance regulation and control when conditions are met, and opening a lateral shunt channel to reduce the flow velocity of a main flow channel. And meanwhile, the adaptive optical imaging unit is synchronously switched to a long integral time mode to collect a fluorescence image. And finally, the data calculation terminal calculates an immunotherapy curative effect evaluation index in combination with cell counting, an omission compensation item and PD-L1 expression intensity. Through synchronous linkage of the flow velocity and exposure, the problem of weak fluorescence signal detection under high-speed flow is solved, and the evaluation accuracy is improved.